Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE versus ERZOFRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE versus ERZOFRI.
ERYTHROMYCIN ETHYLSUCCINATE vs ERZOFRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin ethylsuccinate is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also have anti-inflammatory and immunomodulatory effects.
Erzofri (paliperidone palmitate) is an atypical antipsychotic. Its mechanism of action is not fully understood but is believed to be mediated through a combination of central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism. It also acts as an antagonist at α1 and α2 adrenergic receptors and H1 histaminergic receptors.
400-800 mg orally every 6 hours or 4 times daily; maximum 4 g/day. Intravenous form available but ethylester is oral only.
Intermittent IV infusion (over 1-2 hours), 100 mg/m² every 2 weeks, or 200 mg/m² every 3 weeks.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in adults with normal renal function; extended to 5-6 hours in patients with severe hepatic impairment; not significantly altered by renal failure.
Terminal elimination half-life approximately 1.5-2 hours. However, due to prolonged inhibition of monoamine oxidase B (MAO-B), clinical effects extend beyond drug presence; enzyme recovery takes several weeks.
Primarily hepatic metabolism and biliary excretion (80-90% as unchanged drug and metabolites into bile); renal excretion accounts for 5-15% of unchanged drug; fecal elimination of unabsorbed drug.
Primarily renal (79% unchanged) and biliary/fecal (15% as metabolites and parent drug); less than 1% in urine as lactam metabolite.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic